|
|
|
Volumn 18, Issue 13 Suppl 10, 2004, Pages 21-24
|
|
Bcl-2 antisense therapy in multiple myeloma.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIBIOTIC;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
ANTISENSE OLIGONUCLEOTIDE;
DEXAMETHASONE;
DOXORUBICIN;
MESSENGER RNA;
NUCLEOTIDE;
OBLIMERSEN;
PROTEIN BCL 2;
ANIMAL;
APOPTOSIS;
DRUG EFFECT;
HUMAN;
METABOLISM;
MULTIPLE MYELOMA;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
REVIEW;
TREATMENT OUTCOME;
ANIMALS;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
APOPTOSIS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DEXAMETHASONE;
DOXORUBICIN;
HUMANS;
MULTIPLE MYELOMA;
OLIGONUCLEOTIDES, ANTISENSE;
PROTO-ONCOGENE PROTEINS C-BCL-2;
RNA, MESSENGER;
THIONUCLEOTIDES;
TREATMENT OUTCOME;
|
|
EID: 14144256684
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (26)
|
|
References (21)
|
